Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | TOP1 | P11387 | 2/20 | 0.45 |
| ▸ | TOP2A | P11388 | 6/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4747785 | 0.92 | CYP2C9 (0.61) | CYP2C9CYP3A4TOP1TOP2ATOP2B | |
| SCHEMBL7007581 | 0.91 | CYP2C9 (0.60) | CYP2C9CYP3A4TOP1TOP2ATOP2B | |
| SCHEMBL7006625 | 0.90 | CYP2C9 (0.63) | CYP2C9CYP3A4TOP1TOP2ATOP2B | |
| SCHEMBL4747757 | 0.89 | CYP2C9 (0.69) | CYP2C9CYP3A4TOP1TOP2ATOP2B | |
| SCHEMBL2670076 | 0.89 | CYP2C9 (0.71) | CYP2C9CYP3A4TOP1TOP2ATOP2B | |
| SCHEMBL2922188 | 0.87 | CYP2C9 (0.60) | CYP2C9CYP3A4TOP1TOP2ATOP2B | |
| SCHEMBL2918401 | 0.85 | CYP2C9 (0.47) | CYP2C9CYP3A4TOP1TOP2ATOP2B | |
| SCHEMBL7005127 | 0.84 | CYP2C9 (0.58) | CYP2C9CYP3A4TOP1TOP2ATOP2B | |
| SCHEMBL2917096 | 0.84 | CYP2C9 (0.60) | CYP2C9CYP3A4TOP1TOP2ATOP2B | |
| SCHEMBL7857527 | 0.84 | CYP3A4 (0.50) | CYP2C9CYP3A4TOP1TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813610-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-7713997-B2 | Pyridonecarboxylic acid derivatives or salts thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20090149440-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-1813610-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-6586420-B1 | Photostable bactericides | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1219618-A1 | QUINOLINECARBOXYLIC ACID DERIVATIVE OR ITS SALT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-0911327-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMA CO LTD (JP) | 2001-12-05 | — | — | EP | disclosed |
| US-6156903-A | Pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6133284-A | EXCELLENT BACTERICIDAL PROPERTIES AND ORAL ABSORPTION; INFECTIONS FROM GRAMNEGATIVE AND -POSITIVE BACTERIA; INTESTINAL ABSORPTION, METABOLIC STABILITY; SIDE EFFECT REDUCTION; NONPHOTOTOXICITY AND NONCYTOTOXICITY | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0992501-A2 | Pyridonecarboxylic acid derivatives as antibacterial agents | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-5998436-A | Pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient | WAKUNAGA PHARMACEUTICALS CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0952151-A2 | Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-27 | — | — | EP | disclosed |
| EP-0911327-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149440-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | SLC7A1, PLPBP, PYCR1 | CYP2C9 331/4885CYP3A4 863/4885TOP1 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.